Mission

At Fibrodyne, we’re on a journey to improve the lives of the millions around the world who are affected by scarring or age-related skin changes. Our breakthrough in fibroblast (skin cell) biology, which unlocks the power of the skin to regenerate itself, makes easy, simple and truly effective scar elimination accessible and affordable to all. 

WHY

Disease. Injury. Surgery. Age. They can all cause scarring or degeneration of the structural integrity of the skin. And every scar, irrespective of its size or type, can – and often does – cause significant physical, psychological or emotional distress to those who live with them. Yet, despite the best efforts of the medical and cosmetic industries, genuinely effective remedies have proved elusive. 

A skin restoration solution that is simple, permanent and affordable by all would be welcomed across the globe. Fibrodyne’s unique technique has been developed to meet this need.

HOW

It is well known that cells called fibroblasts make the collagen protein that gives skin its structure. But the Fibrodyne team have shown that different types of fibroblasts play different roles in skin restoration. By removing fibroblasts from healthy skin, and injecting them into the same person’s scar tissue, the scar can be restored to normal appearance and function.

FOR
PATIENTS

Scars can have profound, often life-impairing, effects on those who have to live with them. Yet, for most people, living with a scar is the only practical choice. Currently, available treatments, either medical or through cosmetic surgery, are not only limited in their efficacy, but are often extremely expensive.

Fibrodyne’s breakthrough radically changes this situation. The company’s Advanced Medical Therapy, based on its recent fibroblast research, successfully shifts the treatment philosophy from scar repair to skin restoration, providing a safe, simple and genuinely effective route to permanently improved skin. 

Image

FOR
PATIENTS

Scars can have profound, often life-impairing, effects on those who have to live with them. Yet, for most people, living with a scar is the only practical choice. Currently, available treatments, either medical or through cosmetic surgery, are not only limited in their efficacy, but are often extremely expensive.

Fibrodyne’s breakthrough radically changes this situation. The company’s Advanced Medical Therapy, based on its recent fibroblast research, successfully shifts the treatment philosophy from scar repair to skin regeneration, providing a safe, simple and genuinely effective route to permanently improved skin. 

FOR
INVESTORS

The global market for skin treatments is extremely large and growing rapidly. The annual US market for anti-scarring treatments, for example, is estimated at $12 billion, while the global market is expected to reach almost $40 billion by 2026, with a CAGR of 9.9%. The commercial and social implications for an Advanced Therapy which is not only proven to deliver significantly better results than existing treatments, but which is also simple and accessible to all, are clear.

Fibrodyne’s breakthrough treatment is such a therapy. Already funded for First-in-Human trials, the Fibrodyne therapy can be rapidly scaled to meet the demand for treatment of extensive scars associated with self-harm, wounds and burns.

Image

FOR
INVESTORS

The global market for skin treatments is extremely large and growing rapidly. The annual US market for anti-scarring treatments, for example, is estimated at $12 billion, while the global market is expected to reach almost $40 billion by 2026, with a CAGR of 9.9%. The commercial and social implications for an Advanced Therapy which is not only proven to deliver significantly better results than existing treatments, but which is also simple and accessible to all, are clear.

Fibrodyne’s breakthrough treatment is such a therapy. Already funded for First-in-Human trials, the Fibrodyne therapy can be rapidly scaled to meet the demand for treatment of extensive scars associated with self-harm, wounds and burns.

THE
SCIENCE

The potential of fibroblasts (skin cells) for treating scars has been known for some time. Until now, however, attempts to realise this potential have proved unsuccessful.

Existing approaches to fibroblast treatments are based on the injection of many unpurified cells from one person into the scar of another. This results in most cells either being rejected by the patient’s immune system, or accumulating in one site. In short, existing treatments are complicated, slow, unreliable and costly.

Fibrodyne’s insight came through a breakthrough in understanding of skin fibroblasts made by the Watt lab: As a consequence of this understanding we realised that fewer cells, used autologously, could address these issues. If beneficial fibroblasts could be isolated from a patient’s skin, and injected into the scar site skin regeneration would be assured and safe. It is a bonus, but a big one, that the speed and simplicity of the Fibrodyne breakthrough also dramatically reduces the cost of the process.

SEE MORE
Image

THE
SCIENCE

The potential of fibroblasts (skin cells) for treating scars has been known for some time. Until now, however, attempts to realise this potential have proved unsuccessful.

Existing approaches to fibroblast treatments are based on the injection of many cells from one person into the scar of another. This results in most cells either being rejected by the patient’s immune system, or accumulating in one site. In short, existing treatments are complicated, slow, unreliable and costly.

Fibrodyne’s insight was to realise that fewer cells, used autologously, could address these issues. If beneficial fibroblasts could be isolated from a patient’s skin, and injected into the scar site skin regeneration would be assured and safe. It is a bonus, but a big one, that the speed and simplicity of the Fibrodyne breakthrough also dramatically reduces the cost of the process.

SEE MORE

OUR TEAM

The Fibrodyne team includes some of the most highly-qualified and experienced professionals in the field of skin research.

With a wide range of complementary skills and interests, they form a creative, scientific and business synergy which is perfectly positioned to realise the full potential of the company’s innovative and disruptive concept.

PROF FIONA
WATT

FRS FMedSci

Fiona Watt is recognised internationally for her research on skin. After gaining her PhD (DPhil) from the University of Oxford, she carried out postdoctoral research at MIT before moving to London to establish her own research group.

Among many honours, she has received the Chanel CE.R.I.E.S. Research Award and the William Montagna Award of the American Society for Investigative Dermatology.

Fiona is a Fellow of the Royal Society, an international member of the National Academy of Sciences and an Honorary Member of the Society for Investigative Dermatology and the Japanese Society for Investigative Dermatology.

Her current research portfolio includes studies of human epidermal stem cells and an exploration of the role of different fibroblasts in skin restoration.

Image

PROF FIONA
WATT

FRS FMedSci

Fiona Watt is recognised internationally for her research on skin. After gaining her PhD (DPhil) from the University of Oxford, she carried out postdoctoral research at MIT before moving to London to establish her own research group.

Among many honours, she has received the Chanel CE.R.I.E.S. Research Award and the William Montagna Award of the American Society for Investigative Dermatology.

Fiona is a Fellow of the Royal Society, an international member of the National Academy of Sciences and an Honorary Member of the Society for Investigative Dermatology and the Japanese Society for Investigative Dermatology.

Her current research portfolio includes studies of human epidermal stem cells and an exploration of the role of different fibroblasts in skin restoration.

DR MAGNUS
LYNCH

MA DPhil MRCS FRCP

Magnus Lynch is a Consultant Dermatologist and Dermatological Surgeon at Guy’s and St Thomas’ NHS Foundation Trust. He graduated in medicine from the University of Cambridge and trained in Dermatology at St John’s Institute of Dermatology, where he also completed a fellowship in Mohs Surgery and advanced Dermatological Surgery. His clinical expertise encompasses the treatment of complex skin cancers, scar revision and regenerative dermatology.

Magnus obtained his DPhil from the University of Oxford and subsequently undertook postdoctoral work in the
Centre for Stem Cells and Regenerative Medicine at King’s College London. He currently leads a research team at King’s College London and his research interests include the application of single cell and spatial transcriptomic approaches to human skin and understanding the roles of fibroblast populations in
scarring, skin cancer and skin aging.

Image

DR MAGNUS
LYNCH

MA DPhil MRCP

A Consultant Dermatologist and Dermatological Surgeon at Guy’s and St Thomas’ NHS Foundation Trust, Magnus Lynch is also a research group leader at the Centre for Stem Cells and Regenerative Medicine, King’s College London. He graduated in medicine from the University of Cambridge and trained in Dermatology at St John’s Institute of Dermatology, where he also completed a fellowship in Mohs Surgery and advanced Dermatological Surgery.

Magnus obtained his DPhil from the University of Oxford and subsequently undertook postdoctoral work in the
Centre for Stem Cells and Regenerative Medicine. His research interests include the application of single cell and spatial transcriptomic approaches to human skin and understanding the roles of fibroblast populations in
scarring and skin aging.

THE FIBRODYNE
ORIGIN STORY...

X-rays; the selective culturing of bacteria; Penicillin. These are just three of many famous examples of accidental discoveries which have radically altered – and often revolutionised – the direction of medical thinking. Now, Fibrodyne’s Advanced Therapy for scar elimination is set to join their illustrious company.

Why? Because it was an accidental discovery by Fiona Watt and her team that led to the creation of Fibrodyne. In Fiona’s case, it was the discovery that a gene, previously thought to be a marker of epidermal stem cells, was instead expressed by skin fibroblasts. This realisation stimulated research, by Fiona and her team, on fibroblasts. They found that there are different types of fibroblasts in the skin, each with a different function.

To Fiona, the implications of this insight were clear. And extremely exciting. Immediately recognising that her research could form the foundation of a new, and much more effective, approach to treating scars, she teamed up with Magnus. Fibrodyne was born.

DIFFERENT FIBROBLASTS FOR
DIFFERENT NEEDS

POWERED BY

Image